Arcus Biosciences, Inc. (New York Stock Exchange:RCUS)
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
Loses money on what it sells.
- Revenue
- $117.0M
- Net income
- -$452.0M
- Net margin
- -386.3%
Little or no net debt.
- Total debt
- $114.0M
- Cash
- $150.0M
- Debt / equity
- 0.25
Comfortably covers what is due within a year.
- Current assets
- $756.0M
- Current liabilities
- $198.0M
- Current ratio
- 3.82
Consumes cash and must keep raising it.
- Operating cash flow
- -$474.0M
- Free cash flow
- -$475.0M
- FCF margin
- -406.0%
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 126.1M
- Share growth (1y)
- 18.9%
- Cash runway
- 4 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
RCUS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 41.00 M | 17.00 M | 33.00 M | 26.00 M | 160.00 M | 28.00 M |
| Revenue Growth (YoY) | -74.38 % | -39.29 % | 26.92 % | -45.83 % | 310.26 % | -80.69 % |
| Cost of Revenue | 0.00 | 2.00 M | 3.00 M | 2.00 M | 0.00 | 0.00 |
| Gross Profit | 41.00 M | 15.00 M | 30.00 M | 24.00 M | 160.00 M | 28.00 M |
| SG&A Expense | 24.00 M | 29.00 M | 26.00 M | 27.00 M | 29.00 M | 28.00 M |
| R&D Expense | 113.00 M | 122.00 M | 121.00 M | 141.00 M | 139.00 M | 122.00 M |
| Operating Expenses | 137.00 M | 149.00 M | 144.00 M | 166.00 M | 168.00 M | 150.00 M |
| Operating Income | -96.00 M | -134.00 M | -114.00 M | -142.00 M | -8.00 M | -122.00 M |
| Pretax Income | -91.00 M | -128.00 M | -98.00 M | -135.00 M | -8.00 M | -112.00 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -91.00 M | -128.00 M | -98.00 M | -135.00 M | -8.00 M | -112.00 M |
| EPS (Basic) | -0.72 | -1.02 | -0.92 | -1.27 | -0.08 | -1.14 |
| EPS (Diluted) | -0.72 | -1.02 | -0.92 | -1.27 | -0.08 | -1.14 |
| Shares Outstanding | 126.10 M | 125.40 M | 107.40 M | 106.50 M | 106.10 M | 98.40 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.